Literature DB >> 28074327

When Should Negative Endobronchial Ultrasonography Findings be Confirmed by a More Invasive Procedure?

Basil S Nasir1, Kazuhiro Yasufuku2, Moishe Liberman3.   

Abstract

The treatment of non-small cell lung cancer is largely dependent on accurate staging in order to determine appropriate therapy. Despite advances in imaging, such as computed tomography and positron emission tomography, invasive mediastinal staging is frequently needed to rule out mediastinal involvement prior to curative-intent stereotactic ablative radiotherapy or surgical resection. Surgical mediastinal staging with mediastinoscopy, or anterior mediastinotomy, were traditionally considered the gold standard for invasive mediastinal staging. Endobronchial and endoscopic ultrasound have emerged as modern techniques that are being used as first-line options instead of surgical staging. As experience is gained with these newer techniques, the need for confirmatory surgical staging continues to diminish. This article addresses the situations in which negative results should be confirmed by a more invasive procedure.

Entities:  

Mesh:

Year:  2017        PMID: 28074327     DOI: 10.1245/s10434-016-5674-5

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Impact of EBUS-TBNA in addition to [18F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC.

Authors:  Maja Guberina; Kaid Darwiche; Hubertus Hautzel; Till Ploenes; Christoph Pöttgen; Nika Guberina; Ken Herrmann; Lale Umutlu; Axel Wetter; Dirk Theegarten; Clemens Aigner; Wilfried Ernst Erich Eberhardt; Martin Schuler; Rüdiger Karpf-Wissel; Martin Stuschke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-05       Impact factor: 9.236

2.  MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): study protocol of a multicenter randomised controlled trial.

Authors:  Jelle E Bousema; Marcel G W Dijkgraaf; Nicole E Papen-Botterhuis; Hermien W Schreurs; Jos G Maessen; Erik H van der Heijden; Willem H Steup; Jerry Braun; Valentin J J M Noyez; Fieke Hoeijmakers; Naomi Beck; Martijn van Dorp; Niels J M Claessens; Birgitta I Hiddinga; Johannes M A Daniels; David J Heineman; Harmen R Zandbergen; Ad F T M Verhagen; Paul E van Schil; Jouke T Annema; Frank J C van den Broek
Journal:  BMC Surg       Date:  2018-05-18       Impact factor: 2.102

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.